UBC Expands Its Evidence Generation Portfolio with Evidinno Research Acquisition
In a significant move within the healthcare research industry, United BioSource LLC (UBC), based in King of Prussia, Pennsylvania, has announced the acquisition of Evidinno Outcomes Research Inc., a renowned research consulting firm located in Vancouver, Canada. This strategic acquisition is set to bolster UBC’s ability to deliver comprehensive evidence generation solutions, particularly in the realms of real-world evidence (RWE), health economics and outcomes research (HEOR), and epidemiology.
Evidinno is recognized for its expertise in synthesizing real-world data into actionable insights that can greatly affect patient care and treatment accessibility. This acquisition positions UBC as a leader in generating evidence that is crucial for the pharmaceutical industry, supporting biopharma partners in developing modernized evidence approaches that focus on optimal patient access and therapy effectiveness.
Aaron Berger, Senior Vice President of Evidence Development Solutions at UBC, emphasized the strategic vision behind this acquisition. He stated that "Evidinno's scientific rigor and technology-enabled workflows deepen our capacity to curate fit-for-purpose evidence and insights on health economics and outcomes for our clients. Together, we will transform the evidence value chain and assist sponsors in answering critical questions regarding the safety and effectiveness of treatments for patients."
As the landscape of healthcare delivery evolves, integrating advanced analytical capabilities and evidence production processes becomes increasingly pivotal. UBC’s full-service late-stage and post-approval research offerings benefit from Evidinno’s seasoned team, comprised of epidemiologists, health economists, and research scientists who are well-versed in conducting high-quality health technology assessments (HTA) and regulatory-grade evidence synthesis.
Dr. Mir Sohail Fazeli, CEO of Evidinno, remarked on how joining UBC represents a significant milestone in amplifying Evidinno’s scientific capabilities. He noted that the collaboration will merge Evidinno's strengths in HTA and regulatory-grade evidence synthesis with UBC's extensive global platform. This synergy is expected to produce robust and decision-ready evidence, ultimately aiming to improve outcomes for patients worldwide.
Evidinno will continue to function as a wholly owned subsidiary of UBC, allowing both organizations to offer an integrated suite of services throughout the clinical development and post-approval processes. By leveraging Evidinno's solutions in real-world research and economic modeling, UBC aims to improve the decision-making resource available to sponsors and enhance overall patient welfare.
Fairmount Partners acted as the exclusive financial advisor to Evidinno during this acquisition, aligning with industry expectations for measurable outcomes amid a dynamic healthcare environment.
Evidinno is recognized for its expertise in synthesizing real-world data into actionable insights that can greatly affect patient care and treatment accessibility. This acquisition positions UBC as a leader in generating evidence that is crucial for the pharmaceutical industry, supporting biopharma partners in developing modernized evidence approaches that focus on optimal patient access and therapy effectiveness.
Aaron Berger, Senior Vice President of Evidence Development Solutions at UBC, emphasized the strategic vision behind this acquisition. He stated that "Evidinno's scientific rigor and technology-enabled workflows deepen our capacity to curate fit-for-purpose evidence and insights on health economics and outcomes for our clients. Together, we will transform the evidence value chain and assist sponsors in answering critical questions regarding the safety and effectiveness of treatments for patients."
As the landscape of healthcare delivery evolves, integrating advanced analytical capabilities and evidence production processes becomes increasingly pivotal. UBC’s full-service late-stage and post-approval research offerings benefit from Evidinno’s seasoned team, comprised of epidemiologists, health economists, and research scientists who are well-versed in conducting high-quality health technology assessments (HTA) and regulatory-grade evidence synthesis.
Dr. Mir Sohail Fazeli, CEO of Evidinno, remarked on how joining UBC represents a significant milestone in amplifying Evidinno’s scientific capabilities. He noted that the collaboration will merge Evidinno's strengths in HTA and regulatory-grade evidence synthesis with UBC's extensive global platform. This synergy is expected to produce robust and decision-ready evidence, ultimately aiming to improve outcomes for patients worldwide.
Evidinno will continue to function as a wholly owned subsidiary of UBC, allowing both organizations to offer an integrated suite of services throughout the clinical development and post-approval processes. By leveraging Evidinno's solutions in real-world research and economic modeling, UBC aims to improve the decision-making resource available to sponsors and enhance overall patient welfare.
Fairmount Partners acted as the exclusive financial advisor to Evidinno during this acquisition, aligning with industry expectations for measurable outcomes amid a dynamic healthcare environment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.